A phase II study of lenalidomide in platinum-sensitive recurrent ovarian carcinoma

Effect of ovarian tumor characteristics on venous thromboembolic risk

(2013) Arvind Bakhru   Journal of Gynecologic Oncology

Lenalidomide in solid tumors

(2012) Angela Segler et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma

(2012) Susana M. Campos et al.   GYNECOLOGIC ONCOLOGY

OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

(2012) Carol Aghajanian et al.   JOURNAL OF CLINICAL ONCOLOGY

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

(2012) Jonathan Ledermann et al.   NEW ENGLAND JOURNAL OF MEDICINE

A prospective clinical trial of lenalidomide with topotecan in women with advanced epithelial ovarian carcinoma

(2011) Jori S. Carter et al.   International Journal of Clinical Oncology

2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer

(2011) Gavin C.E. Stuart et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer

(2010) Michael Friedlander et al.   GYNECOLOGIC ONCOLOGY

Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study

(2010) Jean A. Hurteau et al.   GYNECOLOGIC ONCOLOGY

Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial

(2010) Gordon JS Rustin et al.   LANCET

Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients

(2009) F. Gay et al.   BLOOD

A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous Å6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer

(2008) Sharad A. Ghamande et al.   GYNECOLOGIC ONCOLOGY

A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma

(2007) Levi S. Downs et al.   CANCER